An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab

Bibliography

• Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-4
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-6
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Avastin: EPAR – Product Information. European Medicines Agency, 2012. Avaiable from: www.ema.europa.eu/ema/index.jsp [Accessed 5 April 2013]
   Google Scholar
• U.S. Food and Drug Administration. Bevacizumab: full prescribing information Genentech, Inc a member of a Roche Group; 2013. Reference ID: 3248476 Avaiable from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm193900.htm [Accessed 5 April 2013]
   Google Scholar
• Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009;10(6):559-68
   PubMed Web of Science ®Google Scholar
• Abu-Hejleh T, Mezhir JJ, Goodheart MJ, et al. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep 2012;14(4):277-84
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Flynn PJ, Kozloff M, et al. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer 2012;48(8):1126-32
   PubMed Web of Science ®Google Scholar
• Dai F, Shu L, Bian Y, et al. Safety of Bevacizumab in Treating Metastatic Colorectal Cancer: a Systematic Review and Meta-analysis of All Randomized Clinical Trials. Clin Drug Investig 2013;33(11):779-88
   PubMed Web of Science ®Google Scholar
• Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14(11):1077-85
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99(16):1232-9.Epub 2007; Erratum in J Natl Cancer Inst 2008;100(2):156-J Natl Cancer Inst 2008;100:9.685
   PubMed Web of Science ®Google Scholar
• Misch M, Czabanka M, Dengler J, et al. D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma. Anticancer Res 2013;33(5):2093-8
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28(20):3239-47
   PubMed Web of Science ®Google Scholar
• Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009;27(30):4966-72
   PubMed Web of Science ®Google Scholar
• Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(10):1252-60
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29(1):11-16
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-19. Erratum in J Clin Oncol 2008;26(18):3110-J Clin Oncol 2009;27(4):653
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013;18(9):1004-12
   PubMed Web of Science ®Google Scholar
• Wagner AD, Thomssen C, Haerting J, Unverzagt S. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev 2012;7:CD008941
   PubMedGoogle Scholar
• Fakih MG, Lombardo JC. Bevacizumab-induced nasal septum perforation. Oncologist 2006;11(1):85-6
   PubMed Web of Science ®Google Scholar
• Traina K, Singh B. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist 2006;11(10):1070-1
   PubMed Web of Science ®Google Scholar
• Marín AP, Sánchez AR, Arranz EE. Nasal septum perforation in a breast cancer patient treated with bevacizumab. Ann Oncol 2009;20(11):1901-2
   PubMed Web of Science ®Google Scholar
• Bylicki O, Boursier C, Peloni JM, Dot JM. Perforation of the nasal septum: a rare complication of bevacizumab. Rev Mal Respir 2012;29(9):1124-6
   PubMed Web of Science ®Google Scholar
• Bengrine-Lefevre L, Afchain P, Chibaudel B, et al. Nasal septum perforation and bevacizumab. Rev Med Interne 2011;32(4):e43-5
   PubMedGoogle Scholar
• Petrelli F, Cabiddu M, Barbara C, Barni S. A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer. Breast Cancer 2011;18(3):226-30
   PubMed Web of Science ®Google Scholar
• Ramiscal JA, Jatoi A. Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients. Acta Oncol 2011;50(4):578-81
   PubMed Web of Science ®Google Scholar
• Mailliez A, Baldini C, Van JT, et al. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer 2010;103(6):772-5
   PubMed Web of Science ®Google Scholar
• Ruiz N, Fernandez-Martos C, Romero I, et al. Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. Br J Cancer 2007;25(22):3376-7
   Google Scholar
• Vignes S, Chaillet M, Cabane J, Piette JC. Nasal septal perforation and systemic disease. Rev Med Interne 2002;23(11):919-26
   PubMed Web of Science ®Google Scholar
• Ramiscal JA, Jatoi A. Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance. Curr Rep 2012;14(4):307-10
   Web of Science ®Google Scholar